AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10584416
Drug: Local addition
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local addition of ketoprofen (1:400) with 4 ml of 1% lidocaine
Trial: 10584416
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (without ketoprofen) with 4 ml of 1% lidocaine
Trial: 8729628
Drug: Albendazole treatment
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Albendazole treatment (N = 49)
Trial: 17044088
Drug: Neuromuscular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuromuscular therapy (NMT)
Trial: 15199082
Drug: Meloxicam (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meloxicam (15 mg qd) for 4 days followed by aspirin (100 mg qd) for 7 days
Trial: 15199082
Drug: Aspirin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (100 mg qd) for 7 days after meloxicam
Trial: 15199082
Drug: Aspirin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (100 mg) for 2 days
Trial: 9393424
Drug: Crestal incision
RxNorm normalized name: INCISED NOTOPTERYGIUM RHIZOME OR ROOT (NOTOPTERYGIUM FRANCHETII)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crestal incision (1,705 implants)
Trial: 9393424
Drug: Remote incision
RxNorm normalized name: INCISED NOTOPTERYGIUM RHIZOME OR ROOT (NOTOPTERYGIUM FRANCHETII)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remote incision (593 implants)
Trial: 7943676
Drug: 2-deoxy-D-glucose (2-DG)
DrugBank: 2-deoxyglucose (DB08831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-deoxy-D-glucose (2-DG) 25.0 mg/kg
Trial: 7943676
Drug: 2-deoxy-D-glucose (2-DG)
DrugBank: 2-deoxyglucose (DB08831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-deoxy-D-glucose (2-DG) 12.5 mg/kg
Trial: 3370038
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of 0.5 mg/kg of indocyanine green (ICG) after 24 hours of head-down bed rest
Trial: 3370038
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of 0.5 mg/kg of indocyanine green (ICG) after being seated for 1 hour
Trial: 25590831
Drug: Synthetic mesh
RxNorm normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic mesh soaked in vancomycin solution (Group 2)
Trial: 23147209
Drug: rimonabant 20 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rimonabant 20 mg/day
Trial: 21519360
Drug: Arbaclofen placarbil
RxNorm normalized name: Arbaclofen Placarbil
DrugBank: Arbaclofen Placarbil (DB08892)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arbaclofen placarbil (AP) 20 mg daily
Trial: 21519360
Drug: Arbaclofen placarbil
RxNorm normalized name: Arbaclofen Placarbil
DrugBank: Arbaclofen Placarbil (DB08892)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arbaclofen placarbil (AP) 40 mg daily
Trial: 21519360
Drug: Arbaclofen placarbil
RxNorm normalized name: Arbaclofen Placarbil
DrugBank: Arbaclofen Placarbil (DB08892)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arbaclofen placarbil (AP) 60 mg daily
Trial: 21519360
Drug: Arbaclofen placarbil
RxNorm normalized name: Arbaclofen Placarbil
DrugBank: Arbaclofen Placarbil (DB08892)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arbaclofen placarbil (AP) 30 mg twice daily
Trial: 16480474
Drug: Propacetamol 2
RxNorm normalized name: 1,2,3-PROPANETRIOL, 2-(4-AMINOBENZOATE)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propacetamol 2 g intravenously, 5 h apart (n = 40)
Trial: 16480474
Drug: Diclofenac 75
RxNorm normalized name: CAPSAICIN 0.025%/DICLOFENAC 75MG KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac 75 mg intramuscularly (n = 40)
Trial: 10729298
Drug: Nasal application
RxNorm normalized name: Nasal Inhalant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal application of oxygen at a constant flow of 2 l/min
Trial: 10729298
Drug: Ambient air
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambient air at a constant flow of 2 l/min
Trial: 8222122
Drug: Enalapril (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (2.5 to 20 mg/d)
Trial: 3532605
Drug: New Rift
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New Rift Valley fever vaccine (formalin‐inactivated, prepared in diploid fetal rhesus lung cells)
Trial: 3532605
Drug: Various vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various vaccine lots
Trial: 29426300
Drug: Oral calcitriol
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral calcitriol 0.5 mcg daily for 6 weeks
Trial: 28861980
Drug: Gushen Antai
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gushen Antai pills combined with progesterone
Trial: 18677973
Drug: Disodium cromoglycate
RxNorm normalized name: Disodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disodium cromoglycate plus reproterol (DSCG/REP) inhalation 20 min before exercise challenge
Trial: 18677973
Drug: Montelukast (MON)
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Montelukast (MON) oral treatment for 3 days
Trial: 10561733
Drug: Perioperative administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perioperative administration of a serine protease inhibitor
Trial: 10561733
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no serine protease inhibitor)
Trial: 8572007
Drug: Antimicrobial therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial therapy (ampicillin-sulbactam and amoxicillin-clavulanic acid)
Trial: 31285376
Drug: Endovascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapy under assumed ideal conditions
Trial: 31285376
Drug: Endovascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapy under current local resources (night time scenarios)
Trial: 31285376
Drug: Endovascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapy under current local resources (daytime scenarios)
Trial: 31285376
Drug: Endovascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapy under assumed ideal conditions (daytime scenarios)
Trial: 25608583
Drug: darunavir 600
RxNorm normalized name: darunavir 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: darunavir 600 mg/100 mg
Trial: 25608583
Drug: darunavir 800
RxNorm normalized name: darunavir 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: darunavir 800 mg/100 mg
Trial: 21708057
Drug: 70 mg
RxNorm normalized name: silybin 70 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70 mg of DHEAS
Trial: 16776915
Drug: Warfarin (adjusted-dose,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (adjusted-dose, INR 2.0 - 3.0)
Trial: 16776915
Drug: Aspirin (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (150 mg - 160 mg once daily)
Trial: 12584227
Drug: IFN-lamivudine combination
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IFN-lamivudine combination therapy
Trial: 9880387
Drug: Early discharge
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early discharge to community therapy
Trial: 9880387
Drug: Therapy, meals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy, meals on wheels, home help visits
Trial: 2678880
Drug: No oral
RxNorm normalized name: Beano Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No oral contraceptives
Trial: 794978
Drug: Mazindol (tricyclic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mazindol (tricyclic compound, non-amphetamine) for 8 weeks
Trial: 23706546
Drug: Intraperitoneal instillation
RxNorm normalized name: Taurolidine 20 mg/mL solution for intraperitoneal instillation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal instillation of 100 mg bupivacaine in 100 mL normal saline solution
Trial: 23706546
Drug: Intraperitoneal instillation
RxNorm normalized name: Taurolidine 20 mg/mL solution for intraperitoneal instillation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal instillation of 100 mg bupivacaine
Trial: 3582722
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg amoxycillin twice daily
Trial: 3582722
Drug: 750 mg
RxNorm normalized name: bran 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg amoxycillin three times daily
Trial: 27802417
Drug: Sodium nitrite
RxNorm normalized name: Sodium Nitrite
DrugBank: Nitrous acid (DB09112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium nitrite (0.3 mg kg ‐1) after placebo
Trial: 27802417
Drug: Sodium nitrite
RxNorm normalized name: Sodium Nitrite
DrugBank: Nitrous acid (DB09112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium nitrite (0.3 mg kg ‐1) after esomeprazole (3×40 mg)
Trial: 26017285
Drug: Pulsatile double-compression-coated
RxNorm normalized name: PULSATILLA PRATENSIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsatile double-compression-coated tablets
Trial: 26017285
Drug: Core mini-tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Core mini-tablets
Trial: 21186984
Drug: triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: triple therapy + kefir (n=46)
Trial: 21186984
Drug: triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: triple therapy + placebo (n=36)
Trial: 21186984
Drug: triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: triple therapy + kefir
Trial: 21186984
Drug: triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: triple therapy + placebo
Trial: 18679637
Drug: Topical preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical preparation containing urea, vitamins, and ceramides for 2 weeks
Trial: 18679637
Drug: Topical urea-only
RxNorm normalized name: urea Topical Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical urea-only preparation
Trial: 14572570
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment groups (CBT, Relaxation, Routine Care)
Trial: 6833677
Drug: Inhaled verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled verapamil
Trial: 6833677
Drug: Inhaled verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled verapamil (before a single inhalation test)
Trial: 29576857
Drug: Naringenin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naringenin (20 mg daily)
Trial: 29576857
Drug: Placebo (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (20 mg daily)
Trial: 27088545
Drug: Systematic antimicrobial
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systematic antimicrobial therapy for all episodes of AB occurring ≤24 months after transplantation (53 patients)
Trial: 27088545
Drug: No antimicrobial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antimicrobial therapy (59 patients)
Trial: 27088545
Drug: Systematic antimicrobial
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systematic antimicrobial therapy for AB (26 patients, per-protocol)
Trial: 27088545
Drug: No antimicrobial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antimicrobial therapy (50 patients, per-protocol)
Trial: 27088545
Drug: Systematic screening
RxNorm normalized name: Integrase Inhibitors, antiinfectives for systematic use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systematic screening and treatment of AB
Trial: 21463799
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid supplement (24 g of an oral supplement containing a leucine metabolite, glutamine, and arginine twice daily)
Trial: 21463799
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no amino acid supplement)
Trial: 9068344
Drug: Mivacurium 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mivacurium 0.6 mg
Trial: 8453193
Drug: Calcium 600
RxNorm normalized name: Calcium 600
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium 600 mg/day
Trial: 8453193
Drug: Calcium plus
RxNorm normalized name: O Calcium Plus D
DrugBank: Cupric oxide (DB11134)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium plus etidronate sodium 400 mg/day for 14 days every 3 months
Trial: 8453193
Drug: Calcium plus
RxNorm normalized name: O Calcium Plus D
DrugBank: Cupric oxide (DB11134)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium plus etidronate plus phosphate (1 g twice daily for 3 days before etidronate)
Trial: 3458431
Drug: Epirubicin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin Regimen A (40‐60 mg/m2 every three weeks)
Trial: 3458431
Drug: Epirubicin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin Regimen B (20‐30 mg/m2/day for 3 days every three weeks)
Trial: 31091608
Drug: Two-dose Hepatitis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-dose Hepatitis B vaccine (HepB) administered on a 0-6 month schedule
Trial: 31091608
Drug: Three-dose Hepatitis
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-dose Hepatitis B vaccine (HepB) administered on a 0-1-6 month schedule
Trial: 31091608
Drug: Challenge dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Challenge dose of Hepatitis B vaccine (HepB)
Trial: 31091608
Drug: Participants with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants with anti-HBs titer <4, 4-6, and 7-9 mIU/ml at follow-up
Trial: 23065023
Drug: Active compound
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active compound (200 μg selenium, 30 mg zinc, 2 mg vitamin A, 180 mg vitamin C, 30 mg vitamin E)
Trial: 23065023
Drug: Active compound
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active compound
Trial: 18723240
Drug: Low-dose CT
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose CT screening annually for 4 years
Trial: 9408114
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIg) treatment (0.4 g/kg for five consecutive days)
Trial: 9408114
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIg) maintenance treatment (0.4 g/kg weekly)
Trial: 31019117
Drug: Anterior subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anterior subcutaneous transposition of the ulnar nerve
Trial: 27769562
Drug: 10-day bismuth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day bismuth quadruple therapy (bismuth tripotassium dicitrate 300 mg four times a day, lansoprazole 30 mg twice daily, tetracycline 500 mg four times a day, and metronidazole 500 mg three times a day)
Trial: 27769562
Drug: 10-day concomitant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day concomitant therapy (lansoprazole 30 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg, all given twice daily)
Trial: 27769562
Drug: 14-day triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-day triple therapy (lansoprazole 30 mg, amoxicillin 1 g, and clarithromycin 500 mg, all given twice daily)
Trial: 20942614
Drug: Two tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two tablets of ibuprofen 200 mg/paracetamol 500 mg
Trial: 20942614
Drug: One tablet
RxNorm normalized name: Hydone Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet of ibuprofen 200 mg/paracetamol 500 mg
Trial: 19032172
Drug: Tincture of
RxNorm normalized name: Tincture of opium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tincture of Opium (TOP) 6.66 mg morphine equivalents, twice daily
Trial: 19032172
Drug: Tincture of
RxNorm normalized name: Tincture of opium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tincture of Opium (TOP) 13.3 mg morphine equivalents, twice daily
Trial: 19032172
Drug: Tincture of
RxNorm normalized name: Tincture of opium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tincture of Opium (TOP) 20 mg morphine equivalents, twice daily
Trial: 19032172
Drug: Tincture of
RxNorm normalized name: Tincture of opium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tincture of Opium (TOP) (all doses)
Trial: 11062193
Drug: Telithromycin (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telithromycin (800 mg perorally once daily for 10 days)
Trial: 11062193
Drug: Clarithromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin (500 mg bid for 10 days)
Trial: 8436153
Drug: Indomethacin 75
RxNorm normalized name: indomethacin 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin 75 mg and Captopril 25 mg (combined treatment)
Trial: 3717319
Drug: Contralateral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contralateral therapy to the normal extremity
Trial: 24772594
Drug: G-suit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-suit
Trial: 24772594
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no G-suit)
Trial: 23321187
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg tolterodine, orally, twice daily
Trial: 20860068
Drug: Venlafaxine (50-75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine (50-75 mg/day depending on weight)
Trial: 15957511
Drug: Pulsed magnetic
RxNorm normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pulsed magnetic field therapy (PMFT)
Trial: 12500022
Drug: Micronized fenofibrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronized fenofibrate (200 mg once daily) in type IIa dyslipidemia
Trial: 12500022
Drug: Pravastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (20 mg once daily) in type IIa dyslipidemia
Trial: 12500022
Drug: Micronized fenofibrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronized fenofibrate (200 mg once daily) in type IIb dyslipidemia
Trial: 12500022
Drug: Pravastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (20 mg once daily) in type IIb dyslipidemia
Trial: 10231206
Drug: Oral metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral metronidazole (OM) 500 mg for adults, 7‐10 mg/kg for children, administered 2‐3 hours before operation and continued postoperatively every 8 hours for three doses if mild to severely inflamed; for complicated appendicitis, the same dose for 3 to 6 days depending on pus presence.
Trial: 10231206
Drug: Ceftizoxime administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftizoxime administered 2 to 3 hours before operation and postoperatively every 6 hours for three doses if mild to severely inflamed; complicated cases received penicillin, chloramphenicol, and gentamicin for 3 to 6 days depending on pus presence.
Trial: 8744845
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination of carteolol 2% and pilocarpine 2% (CBS 341 A) eye-drops
Trial: 31865938
Drug: FPG ≥4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FPG ≥4.5 mmol/L
Trial: 24372613
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of l-theanine
Trial: 24372613
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of l-theanine
Trial: 24372613
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg of l-theanine
Trial: 22158729
Drug: Low protein
RxNorm normalized name: Low protein mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low protein diet (0.5 g protein · kg BW(‐1) · d(‐1))
Trial: 22158729
Drug: High protein
RxNorm normalized name: Vital High Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High protein diet (2.0 g protein · kg BW(‐1) · d(‐1))
Trial: 18339272
Drug: Oral metoprolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral metoprolol treatment
Trial: 18339272
Drug: Oral rehydration
RxNorm normalized name: Oral rehydration salt formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rehydration salt treatment